Business · 27/02/2012Updated: 10/17/2026 · 1 min read
FDA Announces Final Decision to Withdraw Breast Cancer Indication for AVASTIN (Bevacizumab) Following Public Hearing
Summary
The FDA Commissioner has made the final decision to revoke the approval of AVASTIN (Bevacizumab) for breast cancer treatment following a public hearing in June 2011, where a proposal to withdraw the approval was discussed.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →